Bone Marrow Stem Cell Infusion Following a Heart Attack - Full Text View

Sponsors and Collaborators:	Minneapolis Heart Institute Foundation Abbott Northwestern Hospital
Information provided by:	Minneapolis Heart Institute Foundation
ClinicalTrials.gov Identifier:	NCT00268307

Purpose

The goal of this study is to determine the safety of giving a patient's own bone marrow-derived stem cells delivered with a catheter (tube) into the coronary arteries (blood vessels of the heart). Stem cells are simple cells produced by the bone marrow that can develop into many types of cells. It is possible that these cells will decrease the size of damage caused to the heart from a heart attack and increase the pumping efficiency of the heart; which can be decreased due to a heart attack. The stem cells will be taken from bone marrow and then given back into the heart vessels.

Condition	Intervention	Phase
Acute Myocardial Infarction	Drug: Autologous, Unfractionated Bone Marrow Mononuclear Cells	Phase I

MedlinePlus related topics: Heart Attack

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Safety/Efficacy Study
Official Title:	Cellular Transplantation of Autologous Bone Marrow-Derived Stem Cells Following Myocardial Infarction

Further study details as provided by Minneapolis Heart Institute Foundation:

Primary Outcome Measures:

Safety as measured by holter monitor, laboratory assessments, and cardiac MRI [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Improvement of left ventricular function as assessed by serial measurements of infarct size and LV function by cardiac MRI in the active treatment group versus placebo. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	60
Study Start Date:	December 2005
Estimated Study Completion Date:	February 2011
Estimated Primary Completion Date:	August 2009 (Final data collection date for primary outcome measure)

Intervention Details:

Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.

Detailed Description:

This protocol will test the hypothesis that an intracoronary infusion of autologous, unfractionated, bone marrow mononuclear cells will attenuate infarct size and improve left-ventricular function in 60 patients following an acute anterior myocardial infarction who have undergone successful revascularization with PTCA/stenting.

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients age at least 21 years of age
Patients with an acute anterior myocardial infarction limited to the proximal or mid-LAD with an artery diameter of at least 2.5 mm.
Ability to undergo cell therapy procedure within 2 to 7 days following acute MI and PTCA/stenting.
Ejection fraction following reperfusion with PTCA/stenting is between 30% and 50% as assessed by left-ventriculography or echocardiography.
Consent to protocol and agree to comply with all follow-up visits and studies.

Exclusion Criteria:

History of sustained ventricular arrhythmias not related to their acute myocardial infarction who do not have an ICD.
Require coronary artery bypass surgery or percutaneous revascularization due to the presence of residual coronary stenosis > 70% luminal obstruction in the non-infarct related vessel.
History of malignancy within the past 5 years excluding non-melanoma skin cancer or cervical cancer in-situ.
History of anemia (Hb < 9.0 mg/dl).
History of thrombocytosis.
PT or PTT greater than the upper limits of normal.
Life expectancy less than one year.
Patients on chronic dialysis.
History of untreated alcohol or drug abuse.
Currently enrolled in another Investigational drug or device trial.
History of stroke or TIA within the past 6 months.
History of severe valvular heart disease (aortic valve area < 1.0 cm2 or > 3+ mitral regurgitation.
Pregnancy
Subjects who are HIV, hepatitis B or C positive.
Patients with active inflammatory or autoimmune disease on chronic immunosuppressive therapy.
Contraindications to cardiac MRI

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00268307

Contacts

Contact: Jay Traverse, MD	612.863.3900	trave004@umn.edu
Contact: Beth C Jorgenson, MA, RN	612.863.7485	beth.jorgenson@allina.com

Locations

United States, Minnesota
Minneapolis Heart Institute Foundation	Recruiting
Minneapolis, Minnesota, United States, 55407
Principal Investigator: Jay Traverse, MD

Sponsors and Collaborators

Minneapolis Heart Institute Foundation

Abbott Northwestern Hospital

Investigators

Principal Investigator:

Jay Traverse, MD

Minneapolis Heart Institute

More Information

click here for more information on this study This link exits the ClinicalTrials.gov site

Responsible Party:	Minneapolis Heart Institute ( Jay Traverse, MD )
Study ID Numbers:	opt001
Study First Received:	December 20, 2005
Last Updated:	September 16, 2008
ClinicalTrials.gov Identifier:	NCT00268307
Health Authority:	United States: Food and Drug Administration

Keywords provided by Minneapolis Heart Institute Foundation:

Cell therapy

Study placed in the following topic categories:

Necrosis
Heart Diseases
Myocardial Ischemia
Vascular Diseases

Ischemia
Infarction
Myocardial Infarction

Additional relevant MeSH terms:

Pathologic Processes
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 15, 2009